{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"ATLAS","nct_id":"NCT03991403","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=atlas-nct03991403. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"Atezolizumab group","type":"EXPERIMENTAL"},{"description":null,"label":"Control group","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2024-03-11","type":"ESTIMATED"},"conditions":["Non-small Cell Lung Cancer"],"enrollment":{"count":228,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Atezolizumab(Tecentriq)","otherNames":[],"type":"DRUG"},{"name":"Pemetrexed","otherNames":[],"type":"DRUG"},{"name":"Bevacizumab","otherNames":[],"type":"DRUG"},{"name":"Carboplatin","otherNames":[],"type":"DRUG"},{"name":"Paclitaxel","otherNames":[],"type":"DRUG"},{"name":"Carboplatin or cisplatin","otherNames":[],"type":"DRUG"}],"last_update":"2023-04-03","lead_sponsor":"Samsung Medical Center","official_title":"Study of Atezolizumab in Combination With Carboplatin + Paclitaxel +Bevacizumab vs With Pemetrexed + Cisplatin or Carboplatin With Stage IV NON-SQUAMOUS NON-SMALL CELL LUNG CANCER With EGFR(+) or ALK(+)","overall_status":"UNKNOWN","phases":["PHASE3"],"primary_completion_date":{"date":"2023-03-11","type":"ACTUAL"},"primary_outcomes":[{"measure":"progression-free survival, PFS","timeFrame":"34month after the first patient is randomized"}],"references":[{"citation":"Bang YH, Park GH, Oh JW, Hwang S, Jeong JG, Lee B, Joe CY, Kim H, Kim J, Park S, Jung HA, Sun JM, Ahn JS, Ahn MJ, Choi YL, Ahn CH, Ali SM, Ock CY, Lee SH. Artificial intelligence-powered spatial analysis of tumor microenvironment in patients with non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitor. J Immunother Cancer. 2025 Oct 31;13(10):e012374. doi: 10.1136/jitc-2025-012374.","pmid":"41173494","type":"DERIVED"},{"citation":"Park S, Kim TM, Han JY, Lee GW, Shim BY, Lee YG, Kim SW, Kim IH, Lee S, Kim YJ, Park JH, Park SG, Lee KH, Kang EJ, Kim JW, Shin SH, Ock CY, Nam BH, Lee J, Jung HA, Sun JM, Lee SH, Ahn JS, Ahn MJ. Phase III, Randomized Study of Atezolizumab Plus Bevacizumab and Chemotherapy in Patients With EGFR- or ALK-Mutated Non-Small-Cell Lung Cancer (ATTLAS, KCSG-LU19-04). J Clin Oncol. 2024 Apr 10;42(11):1241-1251. doi: 10.1200/JCO.23.01891. Epub 2023 Oct 20.","pmid":"37861993","type":"DERIVED"}],"start_date":{"date":"2019-08-27","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC","url":"https://clinicaltrials.gov/study/NCT03991403"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/atlas-nct03991403"}